{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:09:09Z","timestamp":1789834149487,"version":"4.0.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatic veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS), a potentially life-threatening complication of hematopoietic cell transplantation (HCT), results from prolonged sinusoidal endothelial cell activation and profound endothelial cell damage, with sequelae. Defibrotide, the only drug approved in the United States and Europe for treating VOD\/SOS post-HCT, has European Commission orphan drug designation for preventing graft-versus-host disease (GvHD), associated with endothelial dysfunction. This endothelial cell protector and stabilizing agent restores thrombo-fibrinolytic balance and preserves endothelial homeostasis through antithrombotic, fibrinolytic, anti-inflammatory, anti-oxidative, and anti-adhesive activity. Defibrotide also preserves endothelial cell structure by inhibiting heparanase activity. Evidence suggests that downregulating p38 mitogen-activated protein kinase (MAPK) and histone deacetylases (HDACs) is key to defibrotide\u2019s endothelial protective effects; phosphatidylinositol 3-kinase\/Akt (PI3K\/AKT) potentially links defibrotide interaction with the endothelial cell membrane and downstream effects. Despite defibrotide\u2019s being most extensively studied in VOD\/SOS, emerging preclinical and clinical data support defibrotide for treating or preventing other conditions driven by endothelial cell activation, dysfunction, and\/or damage, such as GvHD, transplant-associated thrombotic microangiopathy, or chimeric antigen receptor T-cell (CAR-T) therapy-associated neurotoxicity, underpinned by cytokine release syndrome and endotheliitis. Further preclinical and clinical studies will explore defibrotide\u2019s potential utility in a broader range of disorders resulting from endothelial cell activation and dysfunction.<\/jats:p>","DOI":"10.1038\/s41409-021-01383-x","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T16:03:57Z","timestamp":1632845037000},"page":"2889-2896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Palomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A.","family":"Kernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0478-3340","authenticated-orcid":false,"given":"Gerhard C.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-7220","authenticated-orcid":false,"given":"Nelson","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"1383_CR1","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/bloodadvances.2017008375","volume":"2","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, Carreras E, Iacobelli M, Nejadnik B. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018;2:1495\u2013509.","journal-title":"Blood Adv"},{"key":"1383_CR2","unstructured":"Defitelio\u00ae (defibrotide) [prescribing information]. Palo Alto, CA, USA: Jazz Pharmaceuticals, Inc.; 2016."},{"key":"1383_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2013.05.001","volume":"59","author":"R Pescador","year":"2013","unstructured":"Pescador R, Capuzzi L, Mantovani M, Fulgenzi A, Ferrero ME. Defibrotide: properties and clinical use of an old\/new drug. Vascul Pharmacol. 2013;59:1\u201310.","journal-title":"Vascul Pharmacol"},{"key":"1383_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/00003495-199345020-00007","volume":"45","author":"KJ Palmer","year":"1993","unstructured":"Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs. 1993;45:259\u201394.","journal-title":"Drugs"},{"key":"1383_CR5","unstructured":"Crystal Research Associates, LLC. Gentium. Drugs for vascular diseases induced by cancer & cancer treatments. Villa Guardia, Italy: Gentium S.r.l.; 2006. https:\/\/cdn2.hubspot.net\/hub\/150154\/file-18094943-pdf\/docs\/gent_eio_06-26-06.pdf."},{"key":"1383_CR6","first-page":"737","volume":"92","author":"PG Richardson","year":"1998","unstructured":"Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737\u201344.","journal-title":"Blood"},{"key":"1383_CR7","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337\u201343.","journal-title":"Blood"},{"key":"1383_CR8","unstructured":"Defitelio\u00ae (defibrotide) [summary of product characteristics]. Villa Guardia, Italy: Gentium SpA; 2018."},{"key":"1383_CR9","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation. Defibrotide for the prevention of graft-versus-host disease. EMA\/COMP\/627684\/2013. London, United Kingdom: European Medicines Agency; 2013."},{"key":"1383_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:781\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1383_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","volume":"4","author":"CQ Fan","year":"2014","unstructured":"Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2014;4:332\u201346.","journal-title":"J Clin Exp Hepatol"},{"key":"1383_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22:400\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1383_CR13","doi-asserted-by":"crossref","unstructured":"Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85:3005\u201320.","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005"},{"key":"1383_CR14","unstructured":"Carreras E. Early complications after HSCT. In: The EBMT handbook, 6th ed. Cham, Switzerland: European School of Haematology; 2012. p. 177\u201395."},{"key":"1383_CR15","doi-asserted-by":"publisher","unstructured":"Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247\u201350. https:\/\/doi.org\/10.1074\/jbc.275.4.2247","DOI":"10.1074\/jbc.275.4.2247"},{"key":"1383_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0268-960X(03)00002-X","volume":"17","author":"JA Coppell","year":"2003","unstructured":"Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev. 2003;17:63\u201370.","journal-title":"Blood Rev"},{"key":"1383_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2011.65","volume":"46","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011;46:1495\u2013502.","journal-title":"Bone Marrow Transplant"},{"key":"1383_CR18","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1182\/blood.V89.6.2184","volume":"89","author":"C Salat","year":"1997","unstructured":"Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood. 1997;89:2184\u20138.","journal-title":"Blood"},{"key":"1383_CR19","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/bmj.316.7141.1328","volume":"316","author":"BJ Hunt","year":"1998","unstructured":"Hunt BJ, Jurd KM. Endothelial cell activation. A central pathophysiological process. BMJ. 1998;316:1328\u20139.","journal-title":"BMJ"},{"key":"1383_CR20","first-page":"139","volume":"60","author":"WC Aird","year":"2008","unstructured":"Aird WC. Endothelium in health and disease. Pharm Rep. 2008;60:139\u201343.","journal-title":"Pharm Rep"},{"key":"1383_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1006\/bbrc.1994.1539","volume":"200","author":"F Bracht","year":"1994","unstructured":"Bracht F, Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun. 1994;200:933\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1383_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14252","volume":"8","author":"N Mor-Vaknin","year":"2017","unstructured":"Mor-Vaknin N, Saha A, Legendre M, Carmona-Rivera C, Amin MA, Rabquer BJ, et al. DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. Nat Commun. 2017;8:14252.","journal-title":"Nat Commun"},{"key":"1383_CR23","doi-asserted-by":"publisher","first-page":"578129","DOI":"10.3389\/fimmu.2020.578129","volume":"11","author":"W Song","year":"2020","unstructured":"Song W, Ye J, Pan N, Tan C, Herrmann M. Neutrophil extracellular traps tied to rheumatoid arthritis: points to ponder. Front Immunol. 2020;11:578129.","journal-title":"Front Immunol"},{"key":"1383_CR24","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1182\/blood.V114.22.4180.4180","volume":"114","author":"T Maeda","year":"2009","unstructured":"Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I. Prolonged administration of defibrotide is non-immunogenic in rats and dogs. Blood. 2009;114:4180.","journal-title":"Blood"},{"key":"1383_CR25","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cpdd.262","volume":"5","author":"K Umemura","year":"2016","unstructured":"Umemura K, Iwaki T, Kimura T, Ogawa C, Fukuda T, Taniguchi S, et al. Pharmacokinetics and safety of defibrotide in healthy Japanese subjects. Clin Pharmacol Drug Dev. 2016;5:548\u201351.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1383_CR26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1182\/blood-2015-10-676114","volume":"127","author":"M Palomo","year":"2016","unstructured":"Palomo M, Mir E, Rovira M, Escolar G, Carreras E, Diaz-Ricart M. What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood. 2016;127:1719\u201327.","journal-title":"Blood"},{"key":"1383_CR27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-2007-998988","volume":"22","author":"FL Pasini","year":"1996","unstructured":"Pasini FL, Frigerio C, Capecchi PL, Ceccatelli L, Messa GL, Franchi M, et al. Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: the adenosine hypothesis. Semin Thromb Hemost. 1996;22:15\u201320.","journal-title":"Semin Thromb Hemost"},{"key":"1383_CR28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1161\/ATVBAHA.111.240291","volume":"32","author":"IM Francischetti","year":"2012","unstructured":"Francischetti IM, Oliveira CJ, Ostera GR, Yager SB, Debierre-Grockiego F, Carregaro V, et al. Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. Arterioscler Thromb Vasc Biol. 2012;32:786\u201398.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1383_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/jcmm.14865","volume":"24","author":"M Palomo","year":"2020","unstructured":"Palomo M, Vera M, Martin S, Torramad\u00e9-Moix S, Martinez-Sanchez J, Belen Moreno A, et al. Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide. J Cell Mol Med. 2020. 2020;24:1713\u201323.","journal-title":"J Cell Mol Med. 2020"},{"key":"1383_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"1383_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.it.2011.04.001","volume":"32","author":"MR Shakespear","year":"2011","unstructured":"Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011;32:335\u201343.","journal-title":"Trends Immunol"},{"key":"1383_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/CIRCULATIONAHA.109.890491","volume":"121","author":"A Zampetaki","year":"2010","unstructured":"Zampetaki A, Zeng L, Margariti A, Xiao Q, Li H, Zhang Z, et al. Histone deacetylase 3 is critical in endothelial survival and atherosclerosis development in response to disturbed flow. Circulation. 2010;121:132\u201342.","journal-title":"Circulation"},{"key":"1383_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.bbmt.2010.11.019","volume":"17","author":"M Palomo","year":"2011","unstructured":"Palomo M, Diaz-Ricart M, Rovira M, Escolar G, Carreras E. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:497\u2013506.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1383_CR34","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3389\/fimmu.2019.02339","volume":"10","author":"J Martinez-Sanchez","year":"2019","unstructured":"Martinez-Sanchez J, Hamelmann H, Palomo M, Mir E, Moreno-Casta\u00f1o AB, Torramade S, et al. Acute graft-vs.-host disease-associated endothelial activation in vitro is prevented by defibrotide. Front Immunol. 2019;10:2339.","journal-title":"Front Immunol"},{"key":"1383_CR35","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4161\/cbt.6.5.3959","volume":"6","author":"GE Koehl","year":"2007","unstructured":"Koehl GE, Geissler EK, Iacobelli M, Frei C, Burger V, Haffner S, et al. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol Ther. 2007;6:686\u201390.","journal-title":"Cancer Biol Ther"},{"key":"1383_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.yjmcc.2020.05.007","volume":"144","author":"JM Grimes","year":"2020","unstructured":"Grimes JM, Grimes KV. p38 MAPK inhibition: a promising therapeutic approach for COVID-19. J Mol Cell Cardiol. 2020;144:63\u20135.","journal-title":"J Mol Cell Cardiol"},{"key":"1383_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/107602960100700308","volume":"7","author":"G Cella","year":"2001","unstructured":"Cella G, Sbarai A, Mazzaro G, Motta G, Carraro P, Andreozzi GM, et al. Tissue factor pathway inhibitor release induced by defibrotide and heparins. Clin Appl Thromb Hemost. 2001;7:225\u20138.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1383_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF00609244","volume":"35","author":"S Coccheri","year":"1988","unstructured":"Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol. 1988;35:151\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"1383_CR39","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/MBC.0b013e32832da1e3","volume":"20","author":"CL Echart","year":"2009","unstructured":"Echart CL, Graziadio B, Somaini S, Ferro LI, Richardson PG, Fareed J, et al. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. Blood Coagul Fibrinolysis. 2009;20:627\u201334.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1383_CR40","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/sj.leu.2403004","volume":"17","author":"A Falanga","year":"2003","unstructured":"Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia. 2003;17:1636\u201342.","journal-title":"Leukemia"},{"key":"1383_CR41","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood.V100.1.334","volume":"100","author":"G Eissner","year":"2002","unstructured":"Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood. 2002;100:334\u201340.","journal-title":"Blood"},{"key":"1383_CR42","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1055\/s-0038-1642468","volume":"71","author":"Q Zhou","year":"1994","unstructured":"Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost. 1994;71:507\u201310.","journal-title":"Thromb Haemost"},{"key":"1383_CR43","first-page":"A529","volume":"Suppl","author":"A Falanga","year":"1999","unstructured":"Falanga A, Marchetti M, Vignoli A, Barbui T. Changes in fibrinolysis, coagulation and endothelium activation in patients given defibrotide for hematopoietic stem cell transplant-associated veno-occlusive disease. Thromb Haemost. 1999;Suppl:A529.","journal-title":"Thromb Haemost"},{"key":"1383_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1527-3466.1991.tb00410.x","volume":"9","author":"S Coccheri","year":"1991","unstructured":"Coccheri S, Biagi G. Defibrotide. Cardiovasc Drug Rev. 1991;9:172\u201396.","journal-title":"Cardiovasc Drug Rev"},{"key":"1383_CR45","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1476-5381.1996.tb15427.x","volume":"118","author":"F Pellegatta","year":"1996","unstructured":"Pellegatta F, Lu Y, Radaelli A, Zocchi MR, Ferrero E, Chierchia S, et al. Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion. Br J Pharmacol. 1996;118:471\u20136.","journal-title":"Br J Pharmacol"},{"key":"1383_CR46","first-page":"669","volume":"18","author":"R Scalia","year":"1996","unstructured":"Scalia R, Kochilas L, Campbell B, Lefer AM. Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: role of P-selectin. Meth Find Exp Clin Pharmacol. 1996;18:669\u201376.","journal-title":"Meth Find Exp Clin Pharmacol"},{"key":"1383_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF00634228","volume":"331","author":"P Lobel","year":"1985","unstructured":"Lobel P, Schror K. Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart. Naunyn Schmiedebergs Arch Pharmacol. 1985;331:125\u201330.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1383_CR48","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1111\/jcmm.15434","volume":"24","author":"D Garc\u00eda-Bernal","year":"2020","unstructured":"Garc\u00eda-Bernal D, Palomo M, Mart\u00ednez CM, Mill\u00e1n-Rivero JE, Garc\u00eda-Guill\u00e9n AI, Blanquer M, et al. Defibrotide inhibits donor leukocyte endothelial interactions and protects against acute graft-versus-host disease. J Cell Mol Med. 2020;24:8031\u201344.","journal-title":"J Cell Mol Med"},{"key":"1383_CR49","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/1078-0432.CCR-08-1270","volume":"15","author":"CS Mitsiades","year":"2009","unstructured":"Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M, et al. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009;15:1210\u201321.","journal-title":"Clin Cancer Res"},{"key":"1383_CR50","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/jnci\/djy032","volume":"110","author":"U Barash","year":"2018","unstructured":"Barash U, Lapidot M, Zohar Y, Loomis C, Moreira A, Feld S, et al. Involvement of heparanase in the pathogenesis of mesothelioma: basic aspects and clinical applications. J Natl Cancer Inst. 2018;110:1102\u201314.","journal-title":"J Natl Cancer Inst"},{"key":"1383_CR51","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1152\/physrev.00014.2004","volume":"85","author":"R Hallmann","year":"2005","unstructured":"Hallmann R, Horn N, Selg M, Wendler O, Pausch F, Sorokin LM. Expression and function of laminins in the embryonic and mature vasculature. Physiol Rev. 2005;85:979\u20131000.","journal-title":"Physiol Rev"},{"key":"1383_CR52","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1182\/blood-2009-08-236455","volume":"115","author":"O Ostrovsky","year":"2010","unstructured":"Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A. Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood. 2010;115:2319\u201328.","journal-title":"Blood"},{"key":"1383_CR53","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1182\/blood-2008-04-149682","volume":"112","author":"L Benimetskaya","year":"2008","unstructured":"Benimetskaya L, Wu S, Voskresenskiy AM, Echart C, Zhou JF, Shin J, et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood. 2008;112:4343\u201352.","journal-title":"Blood"},{"key":"1383_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/1024533031000084231","volume":"8","author":"M Kaleelrahman","year":"2003","unstructured":"Kaleelrahman M, Eaton JD, Leeming D, Bowyer K, Taberner D, Chang J, et al. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). Hematology. 2003;8:91\u201395.","journal-title":"Hematology"},{"key":"1383_CR55","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","volume":"16","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16:1005\u201317.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1383_CR56","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656\u201365.","journal-title":"Blood"},{"key":"1383_CR57","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15267","volume":"181","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Br J Haematol. 2018;181:816\u201327.","journal-title":"Br J Haematol"},{"key":"1383_CR58","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301\u20139.","journal-title":"Lancet"},{"key":"1383_CR59","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals stops enrollment in phase 3 study evaluating defibrotide for the prevention of veno-occlusive disease [press release]. New York, NY: PR Newswire Association LLC; 2020."},{"key":"1383_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.transci.2016.01.009","volume":"54","author":"E Tekg\u00fcnd\u00fcz","year":"2016","unstructured":"Tekg\u00fcnd\u00fcz E, Kaya AH, Bozda\u011f SC, Ko\u00e7ubaba \u015e, Kay\u0131k\u00e7\u0131 \u00d6, Namdaro\u011flu S, et al. Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation? Transfus Apher Sci. 2016;54:30\u201334.","journal-title":"Transfus Apher Sci"},{"key":"1383_CR61","unstructured":"ClinicalTrials.gov. An open-label study of defibrotide for the prevention of acute graft-versus-host-disease (AGvHD). 2020."},{"key":"1383_CR62","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/bmt.2016.351","volume":"52","author":"L Yeates","year":"2017","unstructured":"Yeates L, Slatter MA, Bonanomi S, Lim F, Ong SY, Dalissier A, et al. Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2017;52:762\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"1383_CR63","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"1383_CR64","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017;7:1404\u201319.","journal-title":"Cancer Discov"},{"key":"1383_CR65","unstructured":"ClinicalTrials.gov. A safety and efficacy study of defibrotide in the prevention of chimeric antigen receptor-t-cell-associated neurotoxicity; 2020."},{"key":"1383_CR66","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.pt.2019.04.010","volume":"35","author":"G Nishanth","year":"2019","unstructured":"Nishanth G, Schluter D. Blood-brain barrier in cerebral malaria: pathogenesis and therapeutic intervention. Trends Parasitol. 2019;35:516\u201328.","journal-title":"Trends Parasitol"},{"key":"1383_CR67","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13430","volume":"105","author":"DS Darbari","year":"2020","unstructured":"Darbari DS, Sheehan VA, Ballas SK. The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management. Eur J Haematol. 2020;105:237\u201346.","journal-title":"Eur J Haematol"},{"key":"1383_CR68","unstructured":"ClinicalTrials.gov. Defibrotide in sickle cell disease-related acute chest syndrome; 2020."},{"key":"1383_CR69","doi-asserted-by":"crossref","unstructured":"Klein OR, Choi SW, Haile A, Ktena YP, Pierce E, Smith M, et al. Defibrotide modulates pulmonary endothelial cell activation and protects against lung inflammation in pre-clinical models of LPS-induced lung injury and idiopathic pneumonia syndrome. Biol Blood Marrow Transplant. 2020;6:S138\u20139.","DOI":"10.1016\/j.bbmt.2019.12.664"},{"key":"1383_CR70","unstructured":"ClinicalTrials.gov. Defibrotide in COVID-19 pneumonia (DEFI-VID19); 2020."},{"key":"1383_CR71","unstructured":"Michigan Institute for Clinical & Health Research. MICHR helps launch novel COVID-19 clinical trial. Ann Arbor, Michigan: MICHR; 2020."},{"key":"1383_CR72","doi-asserted-by":"publisher","unstructured":"Richardson E, Carlo-Stella C, Jara R, Vlodavsky I, Iacobelli M, Fareed J et al. Response to Maccio et al., \u201cMultifactorial pathogenesis of COVID-19-related coagulopathy: can defibrotide have a role in the early phases of coagulation disorders?\u201d. J Thromb Haemost. 2020. https:\/\/doi.org\/10.1111\/jth.15088","DOI":"10.1111\/jth.15088"},{"key":"1383_CR73","unstructured":"EBMT. Haematological therapies at the crossroads of the COVID-19 pandemic. Special session presented at: EBMT 2020 Annual Meeting; September 1, 2020; Madrid, Spain."},{"key":"1383_CR74","doi-asserted-by":"crossref","unstructured":"Belsey J, Kemadjou EN, Isaila M, Villa KF. Cost-effectiveness of defibrotide for the treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) with multi-organ dysfunction (MOD) post-hematopoietic Stem cell transplantation (HSCT) in Canada. Blood. 2018;132 Suppl 1:4702.","DOI":"10.1182\/blood-2018-99-111396"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01383-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T21:05:03Z","timestamp":1666991103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01383-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01383-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"23 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PGR has served on advisory committees and has received research funding from Jazz Pharmaceuticals. MP has received honoraria in speaker\u2019s fee for a symposium from Jazz Pharmaceuticals. NAK received grants from Gentium during the conduct of the study, and her research was supported by the National Cancer Institute of the National Institutes of Health under award number P30 CA008748; the content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health. GCH has stocks\/ownership interests in Sangamo Bioscience, Axim Biotechnologies, Juno Therapeutics, Kite Pharma, Novartis, Insys Therapeutics, AbbVie, GW Pharmaceuticals, Cardinal Health, Immunomedics, Endocyte, Clovis Oncology, Cellectis, Aetna, CVS Health, Celgene, Bluebird Bio, Bristol Myers Squibb\/Medarex, CRISPR Therapeutics, IDEXX Laboratories, Johnson & Johnson, Pfizer, Procter & Gamble, Vertex, Bayer, and Scotts-Miracle; has served in advisory\/consulting roles for Pfizer, Kite Pharma, Incyte, and Jazz Pharmaceuticals; has received research funding from Takeda, Jazz Pharmaceuticals, Astellas, Incyte, and Pharmacyclics; and has received travel, accommodations, and\/or expense reimbursement from Kite Pharma, Incyte, Pfizer, Falk Foundation, Jazz Pharmaceuticals, and Astellas Pharma. NC has nothing to disclose. EC has received research funds and honoraria in speaker\u2019s fees for symposia from Jazz Pharmaceuticals\/Gentium Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}